9/0.1, v/v). After an initial period of 2 min at 5% B, the proportion of B was increased linearly to 25% (at 3 min), 90% (at 14.8 min) and 96% (at 15 min). After a hold-time of 2 min at 96% B, the

column was buy Ibrutinib re-equilibrated for 2 min at 5% B. The temperature of the column oven was 35 °C, while the flow rate was set to 600 μL/min. The injection volume was 5 μL. Mass spectrometric analysis was performed in the selected reaction monitoring (SRM) mode after negative electrospray ionization. The following settings were used: source temperature 550 °C, curtain gas 20 psi, nebulizer gas (GS1) 50 psi, auxiliary gas (GS2) 50 psi, ion spray voltage −4000 V, collision gas high, SRM dwell time 50 ms. Mass Dasatinib order transitions used for the analysis as well as optimized

analyte-dependent parameters are given in Table 1. Validation of the method included determination of the apparent recovery (RA), the signal suppression/enhancement (SSE), the recovery of the extraction step (RE), the repeatability (RSD) as well as the limits of detection and quantification (LODs and LOQs). Feces and urine samples of the control group were spiked in triplicate with appropriate amounts of standard mixtures prior to and after extraction. Method validation for feces was performed for DON, DOM-1 and D3G at 8 different spiking levels, corresponding to a working range of 1–300 ng/mL in the measurement solutions. For urine, method performance characteristics were determined for DON, DOM-1, D3G

and DON-GlcA in an extended working range of 1–500 ng/mL in the measurement solutions (9 spiking levels). All samples were analyzed using Analyst software version 1.5.2 (AB Sciex, Foster City, CA). By plotting the peak area versus the analyte concentration in MS Excel (2007), linear regressions curves were obtained for each analyte and sample type. Thereof, the performance characteristics RA and SSE were calculated according to Sulyok et al. (2006). The RE was calculated by dividing the obtained mean values for the RA by the determined mean values for the SSE. The repeatability of the method, expressed as relative standard deviation, was calculated from the triplicate analysis of the different spiking Oxymatrine levels. The LODs and LOQs were calculated from the spiking levels closest to a signal-to-noise ratio (S/N) of 3:1 and 10:1, respectively, and assessed for both, liquid standards and spiked samples. Urine and feces samples from treated rats were extracted and analyzed in duplicate. Sample concentrations were determined on the basis of peak areas using external calibration (Analyst). If samples showed signal-to-noise ratios lower than 3:1 and 10:1, respectively, half of the LOD and half of the LOQ values were used for further calculations. Obtained mean values were corrected for the RA.